A Polygenic Risk Score Assessment Reveals More Screening Participants with Clinically Significant Prostate Cancer Than Those Who Would Be Identified with PSA or MRI By Ogkologos - April 30, 2025 639 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BARCODE1 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR How to Spot Suspicious Herb and Supplement Claims During Cancer June 29, 2021 2022 ASCO Annual Meeting Research Round Up: New Research in Lung... September 15, 2022 New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... May 20, 2021 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Load more HOT NEWS Study Identifies Potential Warning Signs of Colorectal Cancer in Younger Adults Ranking of Molecular Alterations in HNSCC According to ESCAT Classification Provides... With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... Brothers Start Nonprofit To Help Fellow Teens Struggling With Mental Health...
